Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy

Trial Profile

Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Stroke; Thrombosis
  • Focus Adverse reactions
  • Acronyms RE-CIRCUIT
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 15 Nov 2017 Results assessing heparin dose administered on the day of ablation and regional differences, presented at the 90th Annual Scientific Sessions of the American Heart Association.
    • 15 Nov 2017 Results of subanalysis assessing regional differences in patient characteristics, ablation procedures and bleeding incidence presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 10 Nov 2017 According to a Boehringer Ingelheim media release, sub-analyses data will be presented at the American Heart Association (AHA) Scientific Sessions 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top